Redbiotec is pleased to announce that it has further validated its complex CMV antigens in two new in vivo (mouse) studies. One performed in house, one by a pharma partner. Redbiotec’s complex CMV antigens showed high neutralizing antibody titers even at low dose, both as standalone product as well as in a formulation combined with another CMV glycoprotein. For further information please do not hesitate to contact schaub@redbiotec.ch.